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ABSTRACT
Background: The majority of existing studies aimed at investigating the incidence and pre-
valence of multidrug-resistance by bacteria have been performed in healthcare settings. 
Relatively few studies have been conducted in community settings, but these have consistently 
shown a high prevalence of multidrug-resistant bacteria in low- and middle-income countries 
(LMICs).
Objectives: To provide an appraisal of the evidence on the high prevalence of multidrug-, 
extensive drug-, and pandrug-resistance in commensal Escherichia coli isolates from human 
sources in community settings in LMICs.
Methods: Using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
guidelines, PubMed, EMBASE, MEDLINE, Web of Science, CINAHL, and Cochrane Library databases 
were systematically searched with the search string: ‘Enterobacteriaceae’, OR ‘E. coli’, OR ‘Escherichia 
coli’, AND ‘antibiotic resistance’, OR ‘antimicrobial resistance’, OR ‘drug-resistance’, AND ‘prevalence’, 
OR ‘incidence’, OR ‘morbidity’, OR ‘odds ratio’, OR ‘risk ratio’, OR ‘confidence interval’, OR ‘p-value’, OR 
‘rate’. Data were extracted and proportional meta-analysis was performed using the Freeman–Tukey 
transformation random effect model.
Results: The prevalence of multidrug-, extensive drug- and pandrug-resistance were extracted 
from articles that met our inclusion criteria and pooled together after a systematic screening of 9,369 
items. The prevalence of multidrug-resistance was 28% of 14,336 total cases of isolates tested, 95% 
CI: 23–32. Extensive drug-resistance was 24% of 8,686 total cases of isolates tested, 95% CI: 14–36. 
Lastly, pandrug-resistance was 5% of 5,670 total cases of isolates tested, 95% CI: 3–8.
Conclusion: This paper provides an appraisal of the evidence on the high prevalence of 
multidrug-, extensive drug- and pandrug-resistance by commensal E. coli in community 
settings in LMICs. Our results call for greater effort to be placed at the community level in 
the design of new and improved public health policies to counter the global threat of 
antibiotic-resistant infections and bacteria.
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Background
Antibiotic resistance (ABR) is one of the most signifi-
cant global health crises of our time[1–4]. Antibiotics 
are medicines used to treat bacterial infections [5]. 
Resistance occurs when the antibiotics become ineffec-
tive in blocking one or more of the pathways involved in 
protein, nucleic acid, cell wall, or folate synthesis, that 
are essential for bacterial survival. In the USA, more 
than 2.8 million people are infected by resistant bac-
teria, and at least 35,000 of these patients die each year 
[1]. In the European Economic Area, 25,000 and 33,000 
people died of infections from resistant bacteria in 2007 
and 2015, respectively, indicating that the burden 
caused by antibiotic resistance is increasing [6,7]. In 
fact, the World Health Organization predicted that by 
2050, the annual number of deaths caused by antimi-
crobial resistance will increase from 700,000 deaths to 
10 million deaths per year globally [8]. The worrying 
fact is that antibiotic resistance is increasing far more 
rapidly than the development of new antibiotics [9]. 
Low- and middle-income countries (LMICs) suffer the 
most from antibiotic resistance because their healthcare 
systems lack the resources to contain numerous infec-
tious diseases that are becoming very difficult and 
expensive to treat due to antibiotic resistance. In high- 
income countries, stringent policies to limit antibiotic 
prescribing have been extensively employed to contain 
the spread of resistant bacteria [10]. Unfortunately, this 
has not been the case in LMICs, especially at the com-
munity level, where antibiotics can be purchase from 
community pharmacists without a doctor’s prescrip-
tion. Antibiotic use has been associated with the car-
riage of resistant commensal E. coli in healthy children 
in community settings worldwide [11].
Extensive antibiotic use leads to an alteration in the gut 
microbiome [12], and the development of resistance by 
CONTACT Emmanuel Nji emmanuel.nji@biostructafrica.org BioStruct-Africa, Vårby, Sweden
GLOBAL HEALTH ACTION                                                                                                              
2020, VOL. 12, 1815272
https://doi.org/10.1080/16549716.2020.1815272
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
commensal bacteria to antibiotics through natural selec-
tion [13]. One of these commensal bacteria is Escherichia 
coli, one of the main reservoirs for transmitting antibiotic 
resistance to pathogenic bacteria through the exchange of 
mobile genetic elements [14,15]. E. coli is an 
Enterobacteriaceae, which is on the World Health 
Organization (WHO) global critical priority list for 
research, discovery, and development of new antibiotics. 
Although LMICs bare the highest-burden of ABR, one 
cannot exclude the fact that a collective approach invol-
ving all sectors is required to reverse its course [1,2,16]. It 
is well recognized that an emphasis has not been placed at 
the community level to contain the spread of multidrug- 
resistant bacteria [17], despite some studies consistently 
showing the existence of a high incidence and prevalence 
of multidrug-resistant commensal E. coli. If this situation 
is not addressed, some of the gains made in modern 
medicine will be reversed due to infections caused by 
multidrug-resistant bacteria becoming more challenging 
and expensive to treat. This paper aimed to provide an 
appraisal on the evidence of a high prevalence of multi-
drug-, extensive drug-, and pandrug-resistant commen-
sal E. coli isolated from healthy humans in LMICs 
community settings (i.e. locations outside of a hospital, 
such as schools and homes). These findings should prove 
useful to researchers, farmers, community pharmacists, 
policymakers, and advocacy groups among others, to 
guide the formulation, amendments, and effective imple-
mentation of antibiotic resistance-related policies to pre-
vent and contain the spread of multidrug-resistant 
bacteria.
Methods
Design
We systematically identified and synthesized studies that 
met the inclusion criteria using the preferred reporting 
items for systematic reviews and meta-analyses 
(PRISMA) guidelines [18].
Type of studies
The studies considered for review were cross-sectional, 
case-control, cohort, and randomized control trials 
whose primary outcome was the prevalence of multi- 
drug resistance in commensal E. coli.
Type of participants (study population)
The participants included persons from the general 
population of all ages and sex, in community settings in 
LMICs.
Outcome of interest
Since most of the studies used different definitions for 
multi-, extensive-, and pandrug resistance, we designed 
alternative definitions, as described in the primary out-
comes sub-section below, to facilitate the inclusion of the 
studies for meta-analysis.
The primary outcomes were:
• Prevalence of multidrug-resistance, i.e. resistance 
to one or more agents in two different antibiotic 
classes (protein, nucleic acid, cell wall, and folate 
synthesis inhibitors) by commensal E. coli in com-
munity settings in LMICs.
• Prevalence of extensive drug-resistance, i.e. resis-
tance to one or more agents in three different anti-
biotic classes by commensal E. coli in community 
settings in LMICs.
• Prevalence of pandrug-resistance, i.e. resistance 
to one or more agents in four different antibiotic 
classes by commensal E. coli in community settings 
in LMICs.
The secondary outcomes were odds ratio, risk 
ratio, rate, 95% confidence interval, and P-value.
Other inclusion and exclusion criteria
We included all articles published in the English language 
in LMICs. Articles containing experiments conducted in 
a country that was an LMICs before transformation into 
a high-income country, according to the World Bank 
definition, if any, were also included. Although this was 
an inclusion criterion, no study was performed in 
a country that had undergone such transformation.
Essential data necessary for inclusion
The studies included were those that utilized the Kirby– 
Bauer disc diffusion or synergy susceptibility test to 
study and report at least one of the primary outcomes.
Data sources
The systematic search was performed in PubMed, 
EMBASE, MEDLINE, Web of Science, CINAHL, and 
Cochrane Library. Reference lists of selected studies and 
unpublished data, such as abstracts from conference pro-
ceedings, dissertations and theses, were also searched.
Systematic search strategy
On 10 March 2018, we searched PubMed, EMBASE, 
MEDLINE, Web of Science, CINAHL, and Cochrane 
Library using MeSH terms for PubMed and the compar-
able terms for the other databases. The search was 
updated on 28 June 2020. The search strings were: 
‘E. coli’, OR ‘Escherichia coli’, OR ‘Enterobacteriaceae’, 
AND ‘antibiotic resistance’, OR ‘antimicrobial resis-
tance’, OR ‘drug resistance’, AND ‘prevalence’, OR ‘inci-
dence’, OR ‘morbidity’, OR ‘odds ratio’, OR ‘risk ratio’, 
OR ‘confidence interval’, OR ‘P-value’, OR ‘rate’. For 
PubMed, EMBASE, and MEDLINE, studies performed 
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in humans and written in the English language were 
selected using the language and species filters. While for 
Web of Science and the Cochrane Library, additional 
search words were added to select for species (‘human*’ 
OR ‘infant*’ OR ‘child*’ OR ‘adolescent*’ OR ‘male*’ OR 
‘female’ OR ‘age’ OR “adult*) since there was no sorting 
filter for species. For CINAHL, neither selection for spe-
cies nor language was performed. Search words were 
designed from the different categories in the PICO 
(Population, Intervention, Comparison and Outcome) 
format.
Study selection
The searched articles were exported to the Rayyan soft-
ware [19], and screening was performed, firstly by title 
and abstract, and finally by reading the full articles. Two 
independent researchers screened every article, and 
a third researcher was available to resolve any disagree-
ments, thereby avoiding selection mistakes.
Data extraction, statistical analysis and quality 
assessment
Data were extracted on an Excel spreadsheet. To ensure 
that no mistakes were made, every article was double- 
checked by an additional researcher. A third researcher 
was available to solve any disagreement that arose dur-
ing the process. Statistical analysis was performed on 
the Joanna Briggs Institute (JBI) SUMARI [20]. 
Proportional meta-analysis was performed using 
a statistical random effect model of Freeman–Tukey. 
In the analysis, multiple resistance for the different 
combinations of antibiotics investigated in the studies 
were included. Quality assessment was performed as 
previously described [21,22]. Primarily, articles that 
combined both disc diffusion or synergy tests with 
polymerase chain reaction (PCR), to confirm both the 
expression and presence of resistant genes were ranked 
as ‘high’. Those that utilized only disc diffusion or 
synergy tests were classified as ‘medium’. Finally, stu-
dies with a sample size of less than 15 and those that 
used single disc diffusion or synergy to determine the 
expression of resistant genes were classified as ‘low’.
Results
Literature search
We obtained 9363 articles from the database search and 
an additional 6 were identified through a review of refer-
ence lists of the included articles (Figure 1). A total of 
7089 articles were screened by title and abstract after 
duplicates were removed in order to exclude those that 
did not meet our inclusion criteria. The full text of 33 
articles were assessed for eligibility, and 18 met our inclu-
sion criteria. The remaining 15 articles were excluded 
because the definition of multiple resistance was not 
clear (n = 3), did not document any multi-, extensive- 
or pandrug-resistant data (n = 11), and could not be 
obtained online (n = 1). A meta-analysis was therefore 
performed from 10 articles.
Study location, strength of evidence, and study 
type
Out of the 10 studies included in the meta-analysis [23– 
32], six were from Asia and four from South America 
(Table 1). Since I2 statistics for heterogeneity can be 
misleading [33,34], we performed an alternative assess-
ment, as described previously [21,22]. From the evalua-
tion, five studies were ranked as high quality, while five 
were ranked as medium. All of the studies were cross- 
sectional except for two, which were cohort studies.
Of the 18 studies included for qualitative synthesis 
(Figure 1), 10 were excluded for the meta-analysis 
because the definition of multi-, extensive-, and pandrug- 
resistance was very vague [23–32] (Table 2). However, 
there was one study in which parts of the data were 
included in the meta-analysis while others were not 
[28]. There were three studies conducted in Africa and 
five in Asia, with four studies classified as high quality and 
four medium quality.
Age, sample size, gender
For all the 18 included studies (Tables 1 and 2), the age 
of the participants ranged from 3 months to 77 years, 
with 7633 participants in total, of which approximately 
55% were male and 45% female (Tables 1 and 2).
High prevalence of multidrug-resistance (MDR) in 
community settings in low- and middle-income 
countries
In this study, multidrug-resistance was defined as the 
resistance of one or more agents in two out of the four 
different classes of antibiotics (protein, nucleic acid, cell 
wall, and folate synthesis). The pooled multidrug- 
resistance was 27% of 14,336 total cases of isolates tested, 
with 95% CI: 23–32 (Figure 2).
High prevalence of extensive-drug resistance 
(XDR) in community settings in low- and middle- 
income countries
In this study, extensive-drug resistance was classified as 
the resistance of one or more agents in three out of the 
four different classes of antibiotics (protein, nucleic acid, 
cell wall, and folate synthesis). The pooled prevalence of 
extensive drug-resistance was 24% of 8686 total cases of 
isolates tested, with 95% CI: 14–36 (Figure 3).
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Emergence of pandrug-resistance (PDR) in 
community settings in low- and middle-income 
countries
Pandrug-resistance was defined as the resistance of one 
or more agents in all four classes of antibiotics (protein, 
nucleic acid, cell wall, and folate synthesis). Pandrug- 
resistance had a pooled prevalence of 5% of 5670 total 
cases of isolates tested, with 95% CI: 3–8 (Figure 4).
Discussion
To contain the spread of multidrug-resistant bacteria, we 
must improve our knowledge of how multidrug-resistance 
Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram of the search results and 
selection of the included studies in the systematic review and meta-analysis. Additional records were identified by screening the 
reference lists of the included studies.
Table 1. Characteristics of studies included for meta-analysis.
Study Age
Number of 
Isolates
Number of 
participants Gender Type of study Country
Strength 
of 
evidence Reference
Bartoloni et al. 
1998
6–72 months 321 321 Male = 165, 
female = 158
Cross-sectional Bolivia Medium [23]
Bartoloni et al. 
2004
1–77 years 108 108 Male = 61, 
female = 47
Cross-sectional Bolivia High [24]
Bartoloni et al. 
2006
6–72 months 1080 3174 Male = 1627, 
female = 1546
Cross-sectional Bolivia High [25]
Dyar et al., 2012 6–60 months 738 818 Male = 445, 
female = 373
Cross-sectional Vietnam Medium [26]
Kalter et al. 2010 3 months– 
3 years
522 523 - Cross-sectional Peru Medium [27]
Mamun et al. 1992 1–5 years 649 64 Male = 33, 
female = 31
Cohort Bangladesh High [28]
Purohit et al. 2017 1–3 years 127 22 - Cross-sectional India High [29]
Shakya et al. 2013 3–14 years 529 529 Male = 304, 
female = 225
Cross-sectional India Medium [30]
Singh et al. 2018 1–14 years 550 550 Male = 396, 
female = 154
Cohort India High [31]
Sahoo et al. 2012 3–9 years 139 417 Male = 230, 
female = 187
Cross-sectional India Medium [32]
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is changing over time in LMICs, including the prevalence 
of multidrug-resistant commensal Escherichia coli in LMIC 
community settings (i.e. locations outside of, a hospital 
inpatient, acute care setting or a hospital clinic setting).
While there is an increase in multidrug-resistant 
pathogenic bacteria in general in community settings 
[41], we have observed that studies on multidrug- 
resistance of commensal E. coli isolated from healthy 
humans have consistently demonstrated very high 
incidences and prevalences in community settings in 
LMICs. This review synthesized eighteen studies that 
reported the prevalence of multidrug-resistance in 
commensal E. coli isolates from human sources in 
community settings in LMICs. Our results showed 
that the prevalence of multidrug- and extensive drug- 
resistance of E. coli at the community level is high in 
LMICs, and more concerning is the emergence of 
pandrug resistance in these settings. This evidence 
should prove useful to inform researchers, commu-
nity pharmacists, and public health policymakers, 
among others, to develop appropriate interventions 
and to formulate and implement policies aimed at 
counteracting the global threats of multidrug- 
resistant infections and bacteria.
Most of the included studies had different defini-
tions of multidrug-, extensive drug-, and pandrug- 
resistance, as also reported by Magiorakos et al. [42]. 
For this study, we classified resistance based on the 
inhibition mechanisms of action (protein, nucleic 
acid, cell wall, and folate synthesis inhibition). 
Multidrug-resistance was defined as the nonsuscept-
ibility of at least one agent in two categories of the 
different mechanisms of action. At least one agent in 
three groups of the mechanism of action was classi-
fied as extensive drug resistance, and at least one 
agent in all four categories of the mechanism of 
action was classified as pandrug-resistance. As 
expected, the heterogeneity between studies was 
very high which may have been because several fac-
tors affect the prevalence of antibiotic resistance, such 
Figure 2. Forest plots showing the prevalence of multidrug-resistance in commensal E. coli isolated from human sources in 
community settings in low- and middle-income countries. In this analysis, the prevalence of the different antibiotic combina-
tions in a single study were all included.
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as previous antibiotic use [11,24,27,43], geographical 
location [26,32], age [24,26], socioeconomic status 
[30,32,43], and exposure to animals [27,44]. These 
factors were different in the included studies (Tables 
1 and 2).
There are several drivers of antibiotic resistance 
whose inter-relationship is very complicated as it 
cuts across different sectors like health, agriculture, 
environment, and industry. The primary driver of 
multidrug-resistance in commensal E. coli in LMICs 
is the relaxed policies surrounding antibiotic access, 
prescription, and use [45]. Commensal E. coli are 
Gram-negative bacteria usually present in the guts 
of humans, animals, birds, and the environment 
[46]. When we ingest antibiotics for the treatment 
of bacterial infections, the commensal E. coli are 
exposed to these antibacterial agents and can develop 
resistance through natural selection [13]. Other dri-
vers of multidrug-resistance in commensal E. coli in 
LMICs have been identified as inappropriate socio-
ecological behaviors, poverty, overcrowding, lack of 
surveillance systems, food and supply chain safety 
issues, and highly contaminated waste effluents [45].
This study is in line with WHO recommendations, 
which call for improved awareness of the multidrug- 
resistance problem's existence as one of the five stra-
tegic objectives to control the problem spelled out in 
the Global action plan on antimicrobial resistance 
[47]. Many people in LMICs are aware of the exis-
tence of antibiotics, but fewer people are aware of 
antibiotic resistance [48]. Our findings will raise 
awareness of the extent of the problem and calls for 
urgent action to address this global health crisis espe-
cially in the current situation of the emergence of 
Figure 3. Forest plots showing the prevalence of extensive drug-resistance in commensal E. coli isolated from human sources in 
community settings in low- and middle-income countries. In this analysis, the prevalence of the different antibiotic combina-
tions in a single study were all included.
Figure 4. Forest plots showing the prevalence of pandrug-resistance in commensal E. coli isolated from human sources in 
community settings in low- and middle-income countries. In this analysis, the prevalence of the different antibiotic combina-
tions in a single study were all included.
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pandemics, like the severe acute respiratory corona-
virus disease 2019 (COVID 19) that has led to a surge 
in the use of antimicrobial drugs within the commu-
nity through self-medication and chemoprophylaxis. 
For COVID19, there has been an extensive use of not 
only antibiotics worldwide, but several medicines 
have also been tested in clinical trials as a potential 
treatment for COVID19 [49–57]. Such is the case for 
remdesivir, which has been authorised for the treat-
ment of COVID19 patients even before approval [52]. 
A combination of both antibiotic and nonantibiotic 
drugs leads to an alteration of the gut microbiome 
that could fuel antibiotic resistance by commensal 
Escherichia coli, which can then be transmitted to 
other pathogenic enteric bacteria, e.g. Salmonella 
typhi, Vibrio cholerae, Helicobacter pylori, among 
others, through the exchange of mobile genetic mate-
rials [12,58–64].
Antibiotic resistance (ABR) is a growing problem 
that requires urgent action to stop its spread. 
Multiple interventions targeting different drivers of 
multidrug-resistance have been recommended [47]. 
Some of these interventions targets community set-
tings and some are tailored to contribute to combat-
ing the challenges of multidrug-resistance. Based on 
the WHO antimicrobial control plan strategic objec-
tives [47], the interventions are classified into the 
following categories; i) those aimed at improving 
awareness and understanding of antibiotic resistance, 
for example, it is recommended that creating partici-
patory videos (participatory documentaries) about 
antibiotic resistance would be useful in creating 
awareness in communities [65]; ii) activities strength-
ening knowledge through active and routine surveil-
lance and research; iii) those focussing on the 
reduction of infections for example improvement in 
sanitation and hygiene, to reduce the demand of 
antibiotics; iv) those that optimize the use of antibio-
tics, for example, the formulation and implementa-
tion of regulations surrounding the use of antibiotics 
coupled with strict monitoring of antibiotic use as 
part of the policy, in addition to the development of 
new screening and diagnostic tools [66]; and v) inter-
ventions ensuring that there is a sustainable invest-
ment in combating antibiotic resistance. A global and 
interdisciplinary approach will fast track implementa-
tion of some of the interventions that may be uni-
versal, for example, the development of new 
screening and diagnostic tools [66]. The recom-
mended interventions have shown to have an impact 
on the combating of multidrug-resistance at the com-
munity level. However, in order to harness the com-
munity’s potential in combating this problem, active 
community engagement and involvement from the 
design to the implementation of the selected inter-
vention should be emphasized and carried out in 
order to allow the implementation of interventions 
that are well adapted to the local context and easy to 
scale up at less cost [67].
To conclude, this study provides an appraisal of 
the evidence on the high prevalence of multidrug-, 
extensive drug resistance, and the emergence of pan-
drug-resistant commensal E. coli from healthy human 
sources in community settings in LMICs. This evi-
dence appraisal calls for urgent action in the fight 
against multidrug-resistance in community settings 
to make antibiotic resistance history.
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